Wang Chi-Chuan, Maciejewski Matthew L, Rao Jaya K, Sheitman Brian B, Sleath Betsy L, Farley Joel F
School of Pharmacy, National Taiwan University, 1, Jen-Ai Road, Section 1, Taipei, 10051, Taiwan,
Adm Policy Ment Health. 2014 Sep;41(5):598-607. doi: 10.1007/s10488-013-0503-7.
This study assessed whether the addition of adjunctive psychotherapy to antipsychotic pharmacotherapy improved antipsychotic persistence and reduced the risk of hospitalization among patients with schizophrenia using 2001-2003 Medicaid claims data from four states: Illinois, Kansas, Minnesota, and North Carolina. New antipsychotic users aged 18 or older were included. Our study showed that adjunctive psychotherapy use was associated with increased antipsychotic persistence during the first two months of treatment but was not associated with risk of hospitalization. Further research is needed to understand how to optimize the benefits of psychotherapy in terms of frequency of appointments, duration, and type.
本研究利用来自伊利诺伊州、堪萨斯州、明尼苏达州和北卡罗来纳州的2001 - 2003年医疗补助索赔数据，评估了在抗精神病药物治疗基础上加用辅助心理治疗是否能提高精神分裂症患者的抗精神病药物治疗依从性并降低住院风险。纳入了年龄在18岁及以上的新使用抗精神病药物的患者。我们的研究表明，在治疗的前两个月，使用辅助心理治疗与抗精神病药物治疗依从性增加有关，但与住院风险无关。需要进一步研究以了解如何在预约频率、治疗时长和类型方面优化心理治疗的益处。
